Skip to main content

Table 3 Adequacy of re-biopsy samples for molecular analysis (N = 53)

From: Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment

  

Detection rate of re-biopsy for malignant cells

  

Cytology

Histology

Overall

ALL

53

41 (77.4)

41 (77.4)

42 (79.2)

EBUS-TBNA

9

9 (100)

8 (88.9)

9 (100)

EBUS-GS

44

32 (72.7)

33 (75.0)

33 (75.0)

  1. Data are presented as number (%)
  2. EBUS-TBNA endobronchial ultrasound-guided transbronchial needle aspiration, EBUS-GS endobronchial ultrasound with a guide sheath
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us